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Previous observations have suggested variability in outcome even within distinct cytogenetic groups. For example, M.D. Anderson Cancer Center data indicated that those patients with monosomy 7 but with some residual normal metaphases had better outcomes than patients with monosomy 7 but without normal metaphases (7). Here we investigated the impact of normal metaphases on MK patients treated in SWOG clinical trials.
We used the data of Medeiros et al (7) , which included 1,344 patients enrolled between 1986 and 2009 in one of ten successive SWOG clinical trials (S8600, S9031, S9034, S9126, S9333, S9500, S9617, S9918, S0106, and S0112) for untreated AML. Induction therapies were grouped into those: (1) with "standard" doses of Ara-C (100 mg/m 2 daily X 7 days), (2) with higher than calculated from the date from registration to the study until death from any cause and was censored at the date of last follow-up for patients last known to be alive. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Association of survival with treatment (grouped as above), age, gender, and number of normal or abnormal cells was examined using univariate and multivariate proportional hazards regression models.
As in Medeiros et al (7) , 176 of the 1,344 patients (13%) were classified as MK. The 176 MK patients had a median age of 61 years; 94% had a complex karyotype (≥ 3 distinct clonal abnormalities); 68% received induction with standard dose of ara-C, 14% with higher Ara-C doses, and 18% without Ara-C. The median survival of the 176 patients was 4 months (95% confidence (Table 1) .
How residual normal metaphases translate into longer survival is unclear. Despite the statistically significant findings the survival of even those MK patients with residual normal cells is very poor (Figure 1 ). While the medical significance of our findings in MK patients is thus limited, our observations suggest that it might be worthwhile to examine the prognostic effect of residual normal metaphases in patients with better prognosis karyotypes. More generally our results provide further evidence for the heterogeneity of even well defined cytogenetic groups. 
